MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

1.38B

Vuru Grade

31.00/100

Current Price

$20.37
+0.15 (+0.74%)

Stability Price

$1.47
Overvalued by 92.78%

Company Metrics

  • P/E 13.83
  • P/S 16.34
  • P/B 3.29
  • EPS -1.26
  • Cash ROIC -5.97%
  • Cash Ratio 8.05
  • Dividend 0 / 0%
  • Avg. Vol. 891,132.00
  • Shares 51.66M
  • Market Cap. 1.38B

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Momenta Pharmaceuticals Inc (MNTA) Disclose Form-4 Insider Selling of James M ...
News Watch International - Aug 25, 2015
Momenta Pharmaceuticals Inc (MNTA): James M. Roach , Senior VP, Development and Chi of Momenta Pharmaceuticals Inc sold 6,812 shares on Aug 17, 2015.
Zacks Short Term Rating on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - American Trade Journal
Momenta Pharmaceuticals Inc (MNTA) Discloses Form 4 Insider Selling : Exec ... - OTC Outlook
The Insider, Michael Franken Sold 20000 Shares of Momenta Pharmaceuticals, Inc ...
OctaFinance.com - Aug 14, 2015
Michael Franken, President - Biosimilars Busines of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) 20.37 +0.15 0.74% is the insider, OctaFinance want to write about today.
Momenta Pharmaceuticals Inc (MNTA) Files Form 4 Insider Selling : Michael ... - Insider Trading Report
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Senior VP - Pharmaceutical Scie ...
OctaFinance.com - Aug 20, 2015
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) 20.37 +0.15 0.74% 's Senior VP - Pharmaceutical Scie John Bishop unloaded 573 shares of the professional & scientific & and technical services's company in an open market trade dated August 20, 2015.
Momenta Pharmaceuticals (MNTA) Marked As A Dead Cat Bounce Stock - TheStreet.com
Momenta Pharmaceuticals, Inc. Price Target Update - News Watch International
Momenta Pharmaceuticals Inc. (MNTA) Has Surged To A New High For The Year
Nasdaq - Jun 1, 2015
Momenta Pharmaceuticals gapped up at the open Monday and has continued to rise in early trade. Shares are now up 1.85 at $21.70 on above average volume.
Here's Why Momenta Pharmaceuticals, Inc. Shares Took Off Today - Motley Fool
Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib ... - GlobeNewswire (press release)
Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher
Motley Fool - Apr 16, 2015
What: Momenta Pharmaceuticals (NASDAQ:MNTA) shares jumped by more than 10% earlier today following news that the FDA had approved Novartis' (NYSE:NVS) and Momenta's biosimilar to Teva Pharmaceuticals (NYSE:TEVA) Copaxone. So What: ...
Momenta Pharmaceuticals Announces Conference Call Details Regarding FDA ... - GlobeNewswire (press release)
First generic drug for multiple sclerosis approved - Boston Globe (subscription)
Momenta Pharmaceuticals Inc (MNTA) Disclose Form-4 Insider Selling of Richard ...
News Watch International - Aug 25, 2015
Momenta Pharmaceuticals Inc (MNTA): Richard P Shea , SVP, CFO of Momenta Pharmaceuticals Inc sold 144 shares on Aug 17, 2015.
Large Outflow of Money Witnessed in Momenta Pharmaceuticals, Inc.
Insider Trading Report - Aug 18, 2015
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) had an volatile session and gained 0.01 points till last call. The price was at $21.68, gaining 0.02% till the last intraday data.
Momenta Pharmaceuticals, Inc. Analyst Rating Update - American Trade Journal
Momenta Pharmaceuticals Inc. (MNTA) Drops 10.52% on August 20
Equities.com - Aug 20, 2015
Momenta Pharmaceuticals Inc. (MNTA) was one of the Russell 2000's biggest losers for Thursday August 20 as the stock slid 10.52% to $20.16, a loss of $-2.37 per share.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Price Target Update
OTC Outlook - Aug 28, 2015
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA): The stock price is expected to reach $ 22.33 in the short term. The number of analysts agreeing with this consensus is 6. The higher estimate for the short term price target is at $31 while the lower ...
Momenta Pharmaceuticals Earns Buy Rating from Sanford C. Bernstein (MNTA) - Watch List News
Friday's Pre-Market Information: Momenta Pharmaceuticals Inc. (MNTA), ImmuCell ... - WallStreet Scope
The Insider, John Bishop Sold 33625 Shares of Momenta Pharmaceuticals, Inc ...
OctaFinance.com - May 13, 2015
The Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) 19.94 -0.22 -1.09% 's Senior VP - Pharmaceutical Scie, John Bishop, the insider made a sale of - 33,625 Momenta Pharmaceuticals Inc's shares, estimated based on $20.7 per share. The sold shares a ...